Lab
Northwell Health Laboratories
Northwell Health Laboratories was paid $198.24M by Medicaid between Jan 2018 and Dec 2024, across 551 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 11% of everything it billed.
33Billing provider infoNORTHWELL HEALTH LABORATORIES
NEW HYDE PARK, NY 11042
NEW HYDE PARK, NY 11042
33aNPI1366543795assigned 09/26/2006
33bProvider typeClinical Medical Laboratory
28Total paid$198.24M
24GClaims10,616,684
24DCodes billed551
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New York
Rank by total paid#1 of 116
Median peer was paid$618K
This provider vs. median321×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 666,956 | $13.46M | |
| 2019 | 901,409 | $14.69M | |
| 2020 | 1,320,214 | $26.85M | |
| 2021 | 1,965,508 | $44.97M | |
| 2022 | 1,933,449 | $40.34M | |
| 2023 | 2,004,774 | $31.38M | |
| 2024incomplete | 1,824,374 | $26.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 11% | 85,516 | 82,654 | $21.30M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 9.1% | 245,260 | 224,096 | $18.07M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.0% | 105,414 | 94,024 | $7.86M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.0% | 246,556 | 244,000 | $5.94M |
| 80053 | Comprehensive metabolic panel | 2.9% | 659,155 | 617,345 | $5.67M |
| 80050 | General health panel | 2.6% | 119,598 | 118,391 | $5.20M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.6% | 182,182 | 179,354 | $5.15M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.6% | 181,990 | 179,231 | $5.13M |
| 80061 | Lipid panel | 2.2% | 430,118 | 426,307 | $4.32M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.1% | 200,187 | 180,977 | $4.21M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.0% | 48,615 | 47,390 | $3.90M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.8% | 340,051 | 334,295 | $3.64M |
539 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 81,904 | $3.63M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 22,883 | $2.93M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 543,682 | $2.79M |
| 86769 | 1.4% | 72,056 | $2.75M | |
| 87581 | 1.3% | 94,738 | $2.65M | |
| 87486 | 1.3% | 94,620 | $2.65M | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 356,452 | $2.63M |
| 86480 | 1.2% | 45,288 | $2.43M | |
| 82607 | 1.2% | 180,831 | $2.35M | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.1% | 49,779 | $2.12M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 1.0% | 6,477 | $2.06M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 64,426 | $1.92M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 69,108 | $1.75M |
| 86003 | <1% | 21,412 | $1.59M | |
| 87081 | <1% | 242,187 | $1.48M | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 204,229 | $1.47M |
| 84439 | <1% | 183,734 | $1.46M | |
| 82746 | <1% | 117,306 | $1.44M | |
| 87800 | <1% | 40,036 | $1.42M | |
| 87507 | <1% | 4,356 | $1.40M | |
| 86780 | <1% | 112,575 | $1.39M | |
| 88185 | <1% | 5,062 | $1.36M | |
| 82728 | <1% | 114,996 | $1.34M | |
| 86703 | <1% | 111,332 | $1.33M | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 2,715 | $1.26M |
| 83970 | <1% | 28,412 | $1.09M | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 27,057 | $1.06M |
| 84403 | <1% | 42,081 | $1.05M | |
| 86803 | <1% | 79,650 | $953K | |
| 86235 | <1% | 19,617 | $925K | |
| 82670 | <1% | 32,945 | $897K | |
| 87536 | <1% | 10,595 | $847K | |
| 84153 | <1% | 53,598 | $769K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 25,597 | $745K |
| 80074 | <1% | 22,806 | $743K | |
| 87631 | <1% | 6,554 | $682K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 11,283 | $677K |
| 83550 | <1% | 104,990 | $671K | |
| 83655 | <1% | 57,279 | $669K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 10,646 | $650K |
| 83001 | <1% | 35,148 | $636K | |
| 83540 | <1% | 124,790 | $635K | |
| 84146 | <1% | 32,017 | $632K | |
| 83002 | <1% | 34,018 | $604K | |
| 84402 | <1% | 24,515 | $597K | |
| 83516 | <1% | 43,347 | $597K | |
| 88312 | <1% | 8,287 | $568K | |
| 88112 | <1% | 12,706 | $560K | |
| 81001 | <1% | 181,438 | $554K | |
| 84702 | <1% | 42,215 | $552K | |
| 84480 | <1% | 51,701 | $542K | |
| 83013 | <1% | 8,623 | $532K | |
| 86618 | <1% | 22,191 | $524K | |
| 86696 | <1% | 26,705 | $519K | |
| 86762 | <1% | 39,515 | $517K | |
| 86360 | <1% | 11,411 | $508K | |
| 87340 | <1% | 53,097 | $497K | |
| 84481 | <1% | 37,728 | $492K | |
| 86376 | <1% | 33,967 | $474K | |
| 86800 | <1% | 33,158 | $472K | |
| 87186 | <1% | 58,604 | $469K | |
| 83020 | <1% | 37,244 | $463K | |
| 84144 | <1% | 23,011 | $454K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 68,238 | $452K |
| 86140 | <1% | 100,127 | $449K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 18,581 | $443K |
| 83880 | <1% | 14,933 | $436K | |
| 81229 | <1% | 790 | $436K | |
| 86765 | <1% | 37,406 | $435K | |
| 81329 | <1% | 5,145 | $428K | |
| 85027 | <1% | 90,007 | $419K | |
| 88360 | <1% | 3,188 | $416K | |
| 86706 | <1% | 45,116 | $401K | |
| 82784 | <1% | 28,429 | $400K | |
| 81513 | <1% | 5,824 | $400K | |
| 86038 | <1% | 43,651 | $392K | |
| 83735 | <1% | 73,442 | $392K | |
| 86160 | <1% | 20,727 | $360K | |
| 82627 | <1% | 16,789 | $357K | |
| 88173 | <1% | 3,634 | $353K | |
| 86787 | <1% | 34,470 | $348K | |
| 88342 | <1% | 5,350 | $335K | |
| 86359 | <1% | 11,440 | $333K | |
| 86147 | <1% | 8,828 | $332K | |
| 84154 | <1% | 19,361 | $317K | |
| 86695 | <1% | 23,435 | $312K | |
| 86665 | <1% | 10,127 | $312K | |
| 82043 | <1% | 62,281 | $310K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 15,397 | $310K |
| 88341 | <1% | 2,300 | $300K | |
| 88184 | <1% | 6,558 | $297K | |
| 86735 | <1% | 28,655 | $295K | |
| 84436 | <1% | 52,715 | $291K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 12,376 | $287K |
| 82785 | <1% | 18,878 | $278K | |
| 82105 | <1% | 24,573 | $273K | |
| 88230 | <1% | 2,059 | $267K | |
| 88142 | <1% | 14,126 | $264K | |
| 86008 | <1% | 4,637 | $262K | |
| 85610 | <1% | 75,615 | $257K | |
| 88307 | <1% | 1,568 | $247K | |
| 83520 | <1% | 12,207 | $244K | |
| 86225 | <1% | 24,256 | $242K | |
| 87529 | <1% | 5,696 | $239K | |
| 86334 | <1% | 11,128 | $238K | |
| 86256 | <1% | 17,767 | $235K | |
| 86146 | <1% | 7,594 | $231K | |
| 86747 | <1% | 11,565 | $228K | |
| 87653 | <1% | 8,494 | $227K | |
| 82652 | <1% | 10,844 | $227K | |
| 87497 | <1% | 7,718 | $224K | |
| 82378 | <1% | 12,657 | $222K | |
| 87625 | <1% | 6,665 | $221K | |
| 83883 | <1% | 11,770 | $216K | |
| 81003 | <1% | 105,304 | $209K | |
| 88304 | <1% | 6,040 | $207K | |
| 82533 | <1% | 9,124 | $205K | |
| 87070 | <1% | 25,614 | $204K | |
| 87799 | <1% | 5,393 | $203K | |
| 83525 | <1% | 16,421 | $202K | |
| 86481 | <1% | 2,838 | $200K | |
| 84550 | <1% | 48,712 | $199K | |
| 85652 | <1% | 87,014 | $196K | |
| 84445 | <1% | 5,012 | $194K | |
| 87077 | <1% | 24,743 | $194K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 66,024 | $190K |
| 86255 | <1% | 17,739 | $190K | |
| 86704 | <1% | 19,722 | $187K | |
| 87522 | Neg quan hep c or qual rna | <1% | 4,544 | $181K |
| 82550 | <1% | 32,367 | $178K | |
| 82570 | <1% | 40,469 | $177K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 362,357 | $167K |
| 87481 | <1% | 6,143 | $167K | |
| 86355 | <1% | 5,755 | $166K | |
| 84100 | <1% | 41,327 | $160K | |
| 86850 | <1% | 21,707 | $158K | |
| 86430 | <1% | 30,091 | $158K | |
| 86617 | <1% | 6,305 | $157K | |
| 86357 | <1% | 5,432 | $156K | |
| 83615 | <1% | 31,337 | $155K | |
| 82248 | <1% | 36,131 | $152K | |
| 86320 | <1% | 5,935 | $149K | |
| 86258 | <1% | 7,992 | $149K | |
| 83498 | <1% | 5,516 | $148K | |
| 80076 | <1% | 19,695 | $146K | |
| 86664 | <1% | 10,039 | $142K | |
| 84235 | <1% | 2,793 | $142K | |
| 84305 | <1% | 7,106 | $142K | |
| 84704 | <1% | 10,648 | $139K | |
| 84425 | <1% | 7,705 | $136K | |
| 80197 | <1% | 12,017 | $135K | |
| 82672 | <1% | 6,146 | $133K | |
| 88264 | <1% | 1,405 | $133K | |
| 85730 | <1% | 27,813 | $132K | |
| 88189 | <1% | 2,509 | $126K | |
| 87517 | <1% | 4,050 | $126K | |
| 84156 | <1% | 36,117 | $123K | |
| 86663 | <1% | 10,042 | $122K | |
| 82677 | <1% | 6,176 | $121K | |
| 86708 | <1% | 11,348 | $120K | |
| 84270 | <1% | 7,272 | $120K | |
| 87493 | <1% | 4,506 | $118K | |
| 82977 | <1% | 19,914 | $118K | |
| 86300 | <1% | 6,037 | $116K | |
| 83519 | <1% | 6,714 | $114K | |
| 84432 | <1% | 9,265 | $112K | |
| 82024 | <1% | 2,827 | $110K | |
| 87521 | Neg quan hep c or qual rna | <1% | 3,337 | $110K |
| 81243 | <1% | 6,559 | $110K | |
| 82274 | <1% | 10,135 | $108K | |
| 83690 | <1% | 17,488 | $107K | |
| 86777 | <1% | 8,353 | $107K | |
| 87088 | <1% | 15,177 | $107K | |
| 88141 | <1% | 6,195 | $107K | |
| 84163 | <1% | 8,179 | $106K | |
| 84466 | <1% | 8,669 | $103K | |
| 86644 | <1% | 7,408 | $101K | |
| 84681 | <1% | 5,045 | $101K | |
| 86336 | <1% | 9,137 | $98K | |
| 81374 | <1% | 2,033 | $98K | |
| 86304 | <1% | 5,046 | $93K | |
| 83521 | <1% | 3,213 | $93K | |
| 86778 | <1% | 7,466 | $92K | |
| 83721 | <1% | 21,005 | $91K | |
| 82088 | <1% | 2,375 | $91K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,386 | $90K |
| 86317 | <1% | 1,112 | $87K | |
| 82157 | <1% | 3,046 | $85K | |
| 88321 | <1% | 1,546 | $85K | |
| 88237 | <1% | 792 | $85K | |
| 86231 | <1% | 7,446 | $85K | |
| 86645 | <1% | 6,846 | $85K | |
| 83090 | <1% | 4,825 | $84K | |
| 82626 | <1% | 3,338 | $83K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 6,330 | $82K |
| 86900 | <1% | 28,806 | $81K | |
| 84238 | <1% | 2,607 | $81K | |
| 80165 | <1% | 7,349 | $80K | |
| 81015 | <1% | 32,348 | $80K | |
| 84207 | <1% | 3,078 | $79K | |
| 83010 | <1% | 6,568 | $78K | |
| 86666 | <1% | 3,338 | $74K | |
| 82150 | <1% | 13,169 | $73K | |
| 84165 | <1% | 8,122 | $73K | |
| 81507 | <1% | 168 | $71K | |
| 83993 | <1% | 4,433 | $71K | |
| 88313 | <1% | 1,020 | $69K | |
| 81422 | <1% | 599 | $69K | |
| 83921 | <1% | 3,864 | $67K | |
| 81376 | <1% | 671 | $66K | |
| 81401 | <1% | 665 | $64K | |
| 87177 | <1% | 7,284 | $63K | |
| 82985 | <1% | 5,132 | $62K | |
| 82950 | <1% | 14,704 | $62K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 21,252 | $62K |
| 87902 | <1% | 300 | $60K | |
| 87075 | <1% | 6,227 | $59K | |
| 82668 | <1% | 3,574 | $59K | |
| 86705 | <1% | 6,339 | $59K | |
| 84590 | <1% | 5,222 | $59K | |
| 86301 | <1% | 3,435 | $58K | |
| 80159 | <1% | 3,633 | $57K | |
| 86341 | <1% | 2,389 | $57K | |
| 86141 | <1% | 5,032 | $56K | |
| 80069 | <1% | 7,491 | $56K | |
| 88291 | <1% | 2,572 | $56K | |
| 82465 | <1% | 16,476 | $54K | |
| 87045 | <1% | 6,210 | $53K | |
| 86709 | <1% | 5,487 | $52K | |
| 85379 | <1% | 5,551 | $52K | |
| 85651 | <1% | 16,305 | $50K | |
| 80414 | <1% | 1,111 | $50K | |
| 86757 | <1% | 1,428 | $49K | |
| 88271 | <1% | 1,001 | $49K | |
| 85613 | <1% | 5,808 | $49K | |
| 82164 | <1% | 3,794 | $48K | |
| 82951 | <1% | 4,943 | $48K | |
| 88275 | <1% | 971 | $48K | |
| 84134 | <1% | 4,609 | $48K | |
| 88108 | <1% | 1,337 | $48K | |
| 86753 | <1% | 3,600 | $47K | |
| 84446 | <1% | 3,421 | $46K | |
| 87338 | <1% | 4,029 | $45K | |
| 84630 | <1% | 4,621 | $45K | |
| 82397 | <1% | 3,532 | $44K | |
| 86901 | <1% | 16,745 | $44K | |
| 82947 | <1% | 14,756 | $43K | |
| 86738 | <1% | 2,052 | $43K | |
| 86364 | <1% | 3,056 | $43K | |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | <1% | 8,269 | $42K |
| 82542 | <1% | 2,120 | $42K | |
| 82103 | <1% | 3,525 | $42K | |
| 81228 | <1% | 162 | $41K | |
| 87901 | <1% | 175 | $41K | |
| 87046 | <1% | 5,974 | $40K | |
| 82610 | <1% | 3,447 | $40K | |
| 82330 | <1% | 4,082 | $40K | |
| 86381 | <1% | 1,847 | $39K | |
| 85045 | <1% | 11,291 | $39K | |
| 81206 | <1% | 426 | $38K | |
| 80177 | <1% | 3,520 | $38K | |
| 84244 | <1% | 2,253 | $38K | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 33,714 | $37K |
| 85732 | <1% | 5,798 | $37K | |
| 87205 | <1% | 9,692 | $35K | |
| 86060 | <1% | 5,776 | $35K | |
| 86592 | <1% | 9,621 | $35K | |
| 88280 | <1% | 1,562 | $34K | |
| 82390 | <1% | 3,657 | $33K | |
| 84479 | <1% | 7,170 | $33K | |
| 82310 | <1% | 10,395 | $32K | |
| 84460 | <1% | 9,962 | $32K | |
| 83835 | <1% | 1,845 | $31K | |
| 87109 | <1% | 2,108 | $30K | |
| 87040 | <1% | 3,204 | $30K | |
| 80230 | <1% | 1,434 | $29K | |
| 84410 | <1% | 601 | $29K | |
| 82172 | <1% | 1,532 | $29K | |
| 80202 | <1% | 2,745 | $28K | |
| 84145 | <1% | 1,295 | $28K | |
| 84450 | <1% | 9,722 | $28K | |
| 82232 | <1% | 2,242 | $28K | |
| 87350 | <1% | 2,959 | $28K | |
| 83695 | <1% | 2,190 | $27K | |
| 86162 | <1% | 1,468 | $27K | |
| 85384 | <1% | 3,416 | $27K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 831 | $26K |
| 82247 | <1% | 9,564 | $26K | |
| 82565 | <1% | 8,080 | $25K | |
| 85244 | <1% | 1,528 | $24K | |
| 86816 | <1% | 1,179 | $24K | |
| 87102 | <1% | 2,762 | $24K | |
| 88187 | <1% | 919 | $24K | |
| 84080 | <1% | 1,917 | $23K | |
| 82525 | <1% | 2,009 | $23K | |
| 86707 | <1% | 2,409 | $23K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,202 | $23K |
| 83003 | <1% | 1,407 | $23K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 1,767 | $22K |
| 82955 | <1% | 2,436 | $22K | |
| 85007 | <1% | 8,981 | $22K | |
| 87900 | <1% | 211 | $22K | |
| 80321 | <1% | 1,514 | $22K | |
| 86774 | <1% | 1,901 | $22K | |
| 82107 | <1% | 404 | $21K | |
| 82166 | <1% | 750 | $21K | |
| 82085 | <1% | 2,652 | $21K | |
| 86812 | <1% | 940 | $21K | |
| 81257 | <1% | 800 | $21K | |
| 82530 | <1% | 1,306 | $21K | |
| 85306 | <1% | 1,258 | $21K | |
| 86677 | <1% | 1,767 | $20K | |
| 84442 | <1% | 1,575 | $20K | |
| 87906 | <1% | 174 | $20K | |
| 81241 | <1% | 938 | $20K | |
| 86215 | <1% | 2,065 | $20K | |
| 84478 | <1% | 7,291 | $20K | |
| 82787 | <1% | 1,687 | $19K | |
| 82308 | <1% | 662 | $19K | |
| 81207 | <1% | 240 | $19K | |
| 85245 | <1% | 1,037 | $18K | |
| 86352 | <1% | 151 | $18K | |
| 80178 | <1% | 2,922 | $18K | |
| 85240 | <1% | 1,299 | $18K | |
| 84155 | <1% | 8,968 | $17K | |
| 88274 | <1% | 480 | $17K | |
| 86593 | <1% | 4,579 | $17K | |
| 80183 | <1% | 1,376 | $17K | |
| 80175 | <1% | 1,335 | $16K | |
| 86200 | <1% | 1,532 | $16K | |
| 82747 | <1% | 1,058 | $15K | |
| 87184 | <1% | 1,844 | $15K | |
| 81270 | <1% | 628 | $15K | |
| 84484 | <1% | 1,429 | $15K | |
| 81500 | <1% | 165 | $15K | |
| 88300 | <1% | 978 | $14K | |
| 85303 | <1% | 1,159 | $14K | |
| 80348 | <1% | 1,421 | $14K | |
| 81240 | <1% | 701 | $14K | |
| 82239 | <1% | 957 | $14K | |
| 84182 | <1% | 285 | $14K | |
| 84520 | <1% | 6,579 | $13K | |
| 82104 | <1% | 988 | $13K | |
| 81256 | <1% | 347 | $13K | |
| 86148 | <1% | 606 | $13K | |
| 87255 | <1% | 595 | $12K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 182 | $12K |
| 82340 | <1% | 2,109 | $12K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 197 | $12K |
| 84075 | <1% | 6,163 | $12K | |
| 84252 | <1% | 775 | $12K | |
| 88285 | <1% | 659 | $11K | |
| 80235 | <1% | 526 | $11K | |
| 86606 | <1% | 788 | $11K | |
| 84597 | <1% | 931 | $11K | |
| 82653 | <1% | 471 | $11K | |
| 86308 | <1% | 2,152 | $11K | |
| 82140 | <1% | 818 | $11K | |
| 85300 | <1% | 1,065 | $10K | |
| 84132 | <1% | 5,350 | $10K | |
| 84378 | <1% | 1,010 | $10K | |
| 82180 | <1% | 1,123 | $10K | |
| 87116 | <1% | 1,021 | $10K | |
| 83631 | <1% | 708 | $10K | |
| 83718 | <1% | 4,338 | $10K | |
| 87496 | <1% | 291 | $10K | |
| 87209 | <1% | 600 | $10K | |
| 86340 | <1% | 784 | $9K | |
| 87449 | <1% | 1,105 | $9K | |
| 81025 | <1% | 1,572 | $9K | |
| 88302 | <1% | 299 | $9K | |
| 86648 | <1% | 866 | $9K | |
| 82552 | <1% | 748 | $8K | |
| 83935 | <1% | 1,381 | $8K | |
| 82040 | <1% | 6,731 | $8K | |
| 80156 | <1% | 669 | $8K | |
| 83930 | <1% | 1,340 | $8K | |
| 87329 | <1% | 955 | $8K | |
| 85305 | <1% | 754 | $8K | |
| 87469 | <1% | 254 | $7K | |
| 82523 | <1% | 443 | $7K | |
| 86658 | <1% | 243 | $7K | |
| 88311 | <1% | 498 | $7K | |
| 83719 | <1% | 757 | $7K | |
| 87563 | <1% | 223 | $7K | |
| 87468 | <1% | 227 | $7K | |
| 87484 | <1% | 227 | $7K | |
| 81443 | <1% | 40 | $7K | |
| 82272 | <1% | 2,169 | $6K | |
| 82656 | <1% | 740 | $6K | |
| 85247 | <1% | 307 | $6K | |
| 87324 | <1% | 943 | $6K | |
| 87254 | <1% | 475 | $6K | |
| 81509 | <1% | 34 | $5K | |
| 87476 | <1% | 179 | $5K | |
| 82139 | <1% | 365 | $5K | |
| 86431 | <1% | 686 | $5K | |
| 85246 | <1% | 243 | $5K | |
| 86682 | <1% | 392 | $5K | |
| 87015 | <1% | 963 | $5K | |
| 84300 | <1% | 1,247 | $5K | |
| 85014 | <1% | 2,596 | $5K | |
| 84449 | <1% | 307 | $5K | |
| 84482 | <1% | 448 | $5K | |
| 85018 | <1% | 2,561 | $5K | |
| 86684 | <1% | 339 | $5K | |
| 88350 | <1% | 45 | $5K | |
| 84295 | <1% | 3,860 | $5K | |
| 87206 | <1% | 965 | $5K | |
| 80162 | <1% | 492 | $5K | |
| 81508 | <1% | 159 | $5K | |
| 86611 | <1% | 269 | $5K | |
| 87641 | <1% | 232 | $5K | |
| 86353 | <1% | 131 | $5K | |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | <1% | 12 | $4K |
| 83605 | <1% | 408 | $4K | |
| 81403 | <1% | 96 | $4K | |
| 80356 | <1% | 610 | $4K | |
| 87328 | <1% | 271 | $4K | |
| 83789 | <1% | 244 | $4K | |
| 86337 | <1% | 223 | $4K | |
| 86870 | <1% | 163 | $4K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 254 | $4K |
| 86880 | <1% | 687 | $4K | |
| 83874 | <1% | 348 | $4K | |
| 81596 | <1% | 113 | $4K | |
| 82657 | <1% | 204 | $3K | |
| 80299 | <1% | 276 | $3K | |
| 86335 | <1% | 142 | $3K | |
| 89051 | <1% | 826 | $3K | |
| 86039 | <1% | 400 | $3K | |
| 87535 | <1% | 135 | $3K | |
| 87210 | <1% | 593 | $3K | |
| 83825 | <1% | 203 | $3K | |
| 87640 | <1% | 231 | $3K | |
| 81219 | <1% | 68 | $3K | |
| 82952 | <1% | 1,059 | $3K | |
| 80051 | <1% | 562 | $3K | |
| 83704 | <1% | 103 | $3K | |
| 86790 | <1% | 200 | $3K | |
| 88346 | <1% | 46 | $3K | |
| 82374 | <1% | 3,369 | $3K | |
| 86632 | <1% | 158 | $3K | |
| 86609 | <1% | 121 | $3K | |
| 83951 | <1% | 51 | $3K | |
| 82365 | <1% | 212 | $3K | |
| 81511 | <1% | 30 | $3K | |
| 86331 | <1% | 189 | $2K | |
| 82435 | <1% | 3,361 | $2K | |
| 88235 | <1% | 12 | $2K | |
| 80185 | <1% | 261 | $2K | |
| 89060 | <1% | 392 | $2K | |
| 86161 | <1% | 212 | $2K | |
| 80349 | <1% | 427 | $2K | |
| 80145 | <1% | 80 | $2K | |
| 82679 | <1% | 98 | $2K | |
| 85660 | <1% | 559 | $2K | |
| 85049 | <1% | 1,041 | $2K | |
| 88365 | <1% | 12 | $2K | |
| 82379 | <1% | 139 | $2K | |
| 87593 | <1% | 64 | $2K | |
| 81382 | <1% | 24 | $1K | |
| 80184 | <1% | 122 | $1K | |
| 84166 | <1% | 88 | $1K | |
| 81255 | <1% | 46 | $1K | |
| 81222 | <1% | 12 | $1K | |
| 87181 | <1% | 328 | $1K | |
| 86631 | <1% | 63 | $1K | |
| 80195 | <1% | 99 | $1K | |
| 84999 | <1% | 244 | $1K | |
| 82595 | <1% | 208 | $1K | |
| 84255 | <1% | 68 | $1K | |
| 81205 | <1% | 45 | $1K | |
| 83529 | <1% | 76 | $1K | |
| 80346 | <1% | 112 | $1K | |
| 86744 | <1% | 95 | $1K | |
| 81338 | <1% | 24 | $1K | |
| 80324 | <1% | 185 | $997.84 | |
| 85270 | <1% | 62 | $987.70 | |
| 81383 | <1% | 12 | $982.17 | |
| 82017 | <1% | 65 | $946.56 | |
| 81251 | <1% | 57 | $933.26 | |
| 86053 | <1% | 37 | $910.05 | |
| 83088 | <1% | 32 | $886.15 | |
| 81250 | <1% | 45 | $879.09 | |
| 86702 | <1% | 175 | $859.73 | |
| 85250 | <1% | 49 | $833.09 | |
| 81400 | <1% | 46 | $810.77 | |
| 85670 | <1% | 168 | $801.19 | |
| 80158 | <1% | 57 | $756.97 | |
| 84133 | <1% | 187 | $709.74 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 19 | $680.33 |
| 81330 | <1% | 45 | $660.82 | |
| 86036 | <1% | 65 | $660.81 | |
| 80169 | <1% | 52 | $651.17 | |
| 81291 | <1% | 95 | $650.80 | |
| 86701 | <1% | 175 | $632.31 | |
| 80055 | <1% | 20 | $619.60 | |
| 83625 | <1% | 50 | $614.99 | |
| 83527 | <1% | 51 | $590.75 | |
| 81290 | <1% | 45 | $573.38 | |
| 83992 | <1% | 411 | $566.76 | |
| 81209 | <1% | 44 | $558.55 | |
| 81260 | <1% | 45 | $555.65 | |
| 80203 | <1% | 42 | $529.85 | |
| 81242 | <1% | 45 | $517.81 | |
| 82384 | <1% | 24 | $511.22 | |
| 82175 | <1% | 27 | $487.44 | |
| 81377 | <1% | 13 | $473.70 | |
| 87101 | <1% | 66 | $429.65 | |
| 80201 | <1% | 37 | $420.74 | |
| 81200 | <1% | 44 | $405.79 | |
| 82575 | <1% | 66 | $382.43 | |
| 86316 | <1% | 26 | $376.84 | |
| 87168 | <1% | 179 | $365.14 | |
| G0452 | Molecular pathology procedure; physician interpretation and report | <1% | 28 | $338.95 |
| 80500 | <1% | 34 | $333.39 | |
| 82436 | <1% | 65 | $319.65 | |
| 86382 | <1% | 13 | $284.69 | |
| 80047 | <1% | 23 | $280.06 | |
| 82300 | <1% | 15 | $263.69 | |
| 86710 | <1% | 22 | $258.33 | |
| 80365 | <1% | 25 | $252.17 | |
| 80358 | <1% | 61 | $238.15 | |
| 80361 | <1% | 47 | $156.34 | |
| 80353 | <1% | 47 | $156.34 | |
| 84591 | <1% | 15 | $155.48 | |
| 84560 | <1% | 27 | $125.71 | |
| 86226 | <1% | 12 | $121.57 | |
| 82705 | <1% | 12 | $46.82 | |
| 89055 | <1% | 12 | $35.89 | |
| 85044 | <1% | 21 | $34.13 | |
| 80354 | <1% | 13 | $25.25 | |
| 85611 | <1% | 12 | $23.62 | |
| 99001 | <1% | 132 | $0.14 | |
| 99080 | 0% | 23,392 | $0.00 | |
| 80339 | 0% | 45 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 23 | $0.00 |
| 80301 | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWRIGHT, LESLIE (BILLING MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Leslie Wright Counseling, LLC | Alma, AR | $26K |
| Williamsburg County Alcohol and Drug Abuse | Kingstree, SC | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.